Navigation Links
Possible predictive biomarker for patients who may respond to autophagy inhibitors
Date:4/8/2013

WASHINGTON, DC Autophagy, the process by which cells that are starved for food resort to chewing up their own damaged proteins and membranes and recycling them into fuel, has emerged as a key pathway that cancer cells use to survive in the face of assault by chemotherapy and radiation. Using drugs to shut down that survival mechanism shows great promise, especially when combined with targeted agents and standard chemotherapies, but until recently, it has been unclear which patients' cancers would respond to that combination therapy.

A team led by researchers from the Perelman School of Medicine at the University of Pennsylvania will present findings (Presentation #1679A) during the AACR Annual Meeting 2013 showing that colon cancer and lung cancer cell lines which expressed a gene known as helicase-like transcription factor (HLTF) tended to be impervious to the effects of the autophagy inhibition drug hydroxycholoroquine (HCQ), a drug originally used as an antimalarial agent. Cells where HLTF is silent, however, appeared to be sensitive to HCQ, which led the team to test HLTF expression in a group of colon cancer patients treated with two chemotherapies (the FOLFOX regimen plus bevacizumab) and HCQ. They found that low expression of HLTF predicted those who would respond to the combination therapy.

Since previous studies have shown that HLTF gene silencing is common in 20 to 40 percent of many epithelial cancers, the Penn team is hopeful their findings could lead to the development of a predictive biomarker to identify patients with other cancers who are most likely to respond to drug therapies involving autophagy inhibitors.

The study will be presented by Ravi Amaravadi, MD, in the Autophagy and Cell Death poster session, Hall A-C, Poster Section 23, at the at the Walter E. Washington Convention Center, 801 Mt Vernon Pl NW, Washington, DC 20001, from 1 p.m. to 5 p.m. ET on Monday, April 8, 2013.


'/>"/>

Contact: Holly Auer
holly.auer@uphs.upenn.edu
215-200-2313
University of Pennsylvania School of Medicine
Source:Eurekalert

Page: 1

Related medicine news :

1. Causes of migraines nearly impossible to determine
2. Early COPD diagnosis possible with nuclear medicine
3. Mesothelioma Victims Center Now Urges Any Retired Industrial or Manufacturing Worker Diagnosed With Mesothelioma To Call Them For The Names Of The Best Possible Law Firms
4. Lung Cancer Asbestos Victims Center Now Urges All Industrial Workers Who Had Exposure to Asbestos at Work and Now Have Lung Cancer to Call Them About Possible Compensation
5. Lung Cancer Asbestos Victims Center Now Urges Nonsmoker US Navy Veterans Who Have Any Type Of Lung Cancer To Call them About Possible Compensation
6. Mesothelioma Victims Center Now Urges All Diagnosed Victims Of Mesothelioma To Call Them Immediately For The Names Of The Best Possible Mesothelioma Law Firms
7. Lung Cancer Asbestos Victims Center Urges US Navy Veterans Stricken With Any Type Of Lung Cancer If They Were Exposed In Asbestos - Possible Significant Compensation
8. Los Angeles Periodontist, Dr. Markzar, is Now Informing Patients about the Possible Connection between Gum Disease and Cardiovascular Disease
9. Lung Cancer Asbestos Victims Center Urges Nonsmokers Now Diagnosed With Lung Cancer To Call Them If They Were Exposed To Asbestos At Work-Possible Financial Compensation
10. Lung Cancer Asbestos Victims Center Now Urges US Navy Veterans Who Now Have Lung Cancer And Were Exposed To Asbestos To Call Them About Possible Financial Compensation
11. Mesothelioma Victims Center Now Urges All Victims Of Mesothelioma To Call Them About Financial Compensation And For The Names Of The Best Possible Mesothelioma Law Firms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 Biocide Systems is ... Wrench Advisors as a consultant and partner for ... accounts. , As Wrench Advisors explains on its ... your organization plan and execute programs by leveraging ... channels. Our experience developing joint venture partnerships and ...
(Date:8/20/2014)... 2014 In its latest blog post, ... program that gets clients off to a great start and ... in, is highlighting an important and possibly life-changing – perhaps ... who wants to understand the insidious nature of drug abuse: ... that drug abuse targets a certain socioeconomic group, such as ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 The award-winning ... (ACPS), has expanded its presence throughout Houston to a ... Eye Institute and Laser Center building. ACPS plastic surgeon ... step forward for ACPS, which has risen to become ... surgery practices in the state since its establishment in ...
(Date:8/20/2014)... August 20, 2014 Texas Medical Research Associates ... The study will help test the effectiveness of a new ... high cholesterol may be eligible to participate in the study. ... in the blood can lead to cardiovascular disease, the no. ... can help reduce the risk of heart disease and stroke. ...
(Date:8/20/2014)... -- White, straight women are much more likely to ... women, a new study finds. Researchers examined data ... 44, who took part in polls in 2002 and ... Family Growth study. In the first poll, 13 ... for infertility. This ranged from getting advice from doctors ...
Breaking Medicine News(10 mins):Health News:Biocide Systems Announces Partnership with Wrench Advisors 2Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 2Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 3Health News:Aesthetic Center for Plastic Surgery Expands Its Reach in Texas 2Health News:Texas Medical Research Associates Announce New Study 2Health News:White Women More Likely to Seek Fertility Treatment: Report 2
... , TUESDAY, April 17 (HealthDay News) -- A group of ... indicators of your chances of living to age 70 than ... challenge the long-held belief that race or the region of ... how long you may live, according to researchers from Stanford ...
... The increasing globalization of the drug supply ... and diversion of medicines, growth of illegal Internet ... into the supply chain. As pharmaceutical companies, regulatory ... determine the best approaches to securing increasingly complex ...
... Randy Dotinga HealthDay Reporter , TUESDAY, April 17 ... value of proton therapy, an expensive new kind of radiation ... the treatment instead of the standard radiation therapy were more ... There also did not appear to be any extra benefit ...
... SEATTLE Larry Corey, M.D., president and director of Fred ... the American Academy of Arts and Sciences, one of the ... centers. , "I,m extremely honored to be in the same ... science, medicine and the arts," Corey said. "I,m also very ...
... April 17 (HealthDay News) -- New research adds to the ... plaques, the brain-clogging fragments that have been associated with Alzheimer,s ... Berlin, researchers report that they were able to use a ... brains of patients whose Alzheimer,s was confirmed after death. ...
... In an analysis of three different types ... cancer, compared with conformal radiation therapy, intensity-modulated radiation ... gastrointestinal adverse effects, hip fractures, and receipt of ... proton therapy was associated with more gastrointestinal adverse ...
Cached Medicine News:Health News:Social Factors May Affect Lifespan More Than Race, Location 2Health News:Global, common approach to pharmaceutical supply chain integrity the focus of workshop 2Health News:Global, common approach to pharmaceutical supply chain integrity the focus of workshop 3Health News:Study Casts Doubt on Value of Pricey Prostate Cancer Therapy 2Health News:Study Casts Doubt on Value of Pricey Prostate Cancer Therapy 3Health News:Hutchinson Center president elected to American Academy of Art and Sciences 2Health News:Hutchinson Center president elected to American Academy of Art and Sciences 3Health News:New Method to Reveal Alzheimer's Marker Shows Promise 2Health News:Study examines adverse effects among different radiation therapies for prostate cancer 2Health News:Study examines adverse effects among different radiation therapies for prostate cancer 3
(Date:8/20/2014)... , August 20, 2014 ... Conducted in the US  KalVista Pharmaceuticals ("KalVista"), ... edema (DME), today announces that it has begun a ... plasma kallikrein inhibitor, KVD001, for the treatment of DME. ... of the Beetham Eye Institute, Joslin Diabetes Center; Harvard ...
(Date:8/19/2014)...  The Alabama Supreme Court, in a 6-3 decision on ... who mislead doctors into believing that prescription medicines the companies ... v. Wyeth, and the decision came after the Supreme Court ... year. Heninger Garrison Davis attorneys Lew Garrison and ... Danny Weeks . The decision won a ...
(Date:8/19/2014)... , Aug. 19, 2014  Northwest Biotherapeutics (NASDAQ: ... DCVax® personalized immune therapies for solid tumor cancers, announced ... last Thursday, August 14, 2014, has closed.  The three-year ... at $7.30 per share of common stock.  The investors ... purchase up to an additional 30% of these notes ...
Breaking Medicine Technology:KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 2NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 3
... Epiphany Biosciences announced,today, the initiation of a ... treatment and management of acute infectious,mononucleosis. Currently, there ... debilitating condition or any other disease caused by,the ... broad spectrum of anti-viral activity,including inhibition of viral ...
... SAN FRANCISCO, Calif., Dec. 6 Rigel,Pharmaceuticals, Inc. (Nasdaq: ... (NYSE: PFE ), has begun a Phase 1 ... syk kinase inhibitor, R343,for the treatment of allergic asthma. ... Under the terms of the companies, 2005 collaboration ...
Cached Medicine Technology:Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis 2Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer 2Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: